Vivek Ramaswamy is founder and Chief Executive Officer of Roivant Sciences. The Roivant family of companies includes multiple wholly-owned or majority-owned biopharmaceutical subsidiaries, each focused on a different disease area. Roivant has 16 drugs in its collective pipeline and has raised over $2.5 billion in capital to date to fund clinical programs and pursue adjacent business opportunities in healthcare.
Prior to founding Roivant, Mr. Ramaswamy was an investor in the biotechnology sector. He currently serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation and he is a member of the Board of Directors of Axovant Sciences, Myovant Sciences, and Roivant Sciences. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.
Vivek Ramaswamy, Founder and Chief Executive Officer, Roivant Sciences
Moderator: Robyn Karnauskas, Director and Senior Analyst for Large Cap Biotechnology, Citi